Helus Pharma CEO Michael Colais Steps Down Immediately

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 day ago

0mins

HELP+2%

Should l Buy HELP?

Source: seekingalpha

Executive Change: Helus Pharma announced that CEO Michael Colais has stepped down immediately at the request of the board, indicating a significant leadership shift that may impact investor confidence.
Interim Leadership: Co-founder and executive chairman Eric So has been appointed as interim CEO to ensure continuity of leadership, helping the company maintain stability during the transition while searching for a new CEO.
Successor Search: The board has initiated a search process for a permanent CEO, a move that could influence the company's strategic direction and future development, prompting investors to monitor subsequent developments closely.
Market Reaction: Helus Pharma's stock rose 8.73% in pre-market trading to $5.98, reflecting market optimism regarding the new leadership and potential confidence in the company's future prospects.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy HELP?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on HELP

Wall Street analysts forecast HELP stock price to rise

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.610

Low

22.00

Averages

41.17

High

55.00

Current: 5.610

Low

22.00

Averages

41.17

High

55.00

TD Cowen

Ritu Baral

initiated

2026-04-13

Reason

TD Cowen

Ritu Baral

Price Target

AI Analysis

2026-04-13

initiated

Reason

TD Cowen analyst Ritu Baral initiated coverage of Helus Pharma with a Buy rating and $8 price target. The firm believes the company's positive Phase 2 adjunct major depressive disorder data for HLP003 and precedent clinical data validating psilocybin-based therapies "de-risk" the company's Phase 3 program. The first Phase 3 two-dose HLP003 dataset is due in Q4, which could drive "major upside" in the shares, the analyst tells investors in a research note. TD models a 2028 launch and peak U.S. sales of $1.3B.

Jefferies

Andrew Tsai

initiated

$22

2026-02-01

Reason

Jefferies

Andrew Tsai

Price Target

$22

2026-02-01

initiated

Reason

Jefferies analyst Andrew Tsai initiated coverage of Helus Pharma with a Buy rating and $22 price target. The firm sees the stock potentially moving "significantly higher" into three catalysts in 2026. Helus' lead asset HLP003 has a 60% probability of success of succeeding in a Phase III in adjunct major depressive disorder, which could result in a 100%-200% share rally, the analyst tells investors in a research note. Jefferies adds that HLP004 is a short-duration psychedelic that has "de-risking" Phase II data in Q1. It also believes Helus finding a CEO is another catalyst.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HELP

Unlock Now

About HELP

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments

1 day agoNewsfilter

Policy Driving Innovation: The White House's new Executive Order aims to accelerate research and regulatory pathways for mental health treatments, reflecting the urgent need for new options, with Helus Pharma actively contributing to this progress through the development of its HLP003 program.
Breakthrough Therapy Designation: Helus Pharma's HLP003 is currently in Phase 3 clinical development and has received Breakthrough Therapy designation from the FDA for adjunctive treatment of major depressive disorder, showcasing the company's strategic positioning to meet market demands.
Funding Support and Coordination: The Executive Order includes increased federal funding to support state-level programs and strengthens coordination among the Department of Health and Human Services, FDA, and Department of Veterans Affairs, creating a favorable policy environment for Helus Pharma's innovative drug development.
Significant Market Potential: Helus Pharma believes that with policy momentum and the accumulation of clinical evidence, more patients will benefit from novel mental health treatments, particularly where existing therapies are insufficient, positioning the company to fill this market gap.

Trump Signs Executive Order to Accelerate Psychedelic Research

1 day agoCNBC

Research Acceleration Policy: President Trump's executive order aims to expedite research on psychedelics like psilocybin and MDMA, although it does not alter drug scheduling, reflecting a focus on a medical-first framework that may pave the way for future cannabis rescheduling.
Positive Market Reaction: Following the signing of the order, psychedelic developers like AtaiBeckley saw stock prices rise approximately 25%, indicating a positive market response to the policy shift and growing investor confidence in the psychedelic sector.
Safety Concerns: The inclusion of ibogaine in the order raises safety concerns due to its potential cardiac risks, despite its applications being studied for PTSD and addiction, highlighting significant barriers to commercialization.
Industry Outlook: While the psychedelic industry lacks a commercial market, the rise of clinical-stage developers suggests that the executive order provides crucial support for the legitimacy of psychedelics, potentially fostering broader acceptance of plant-based alternative medicines in the future.

White House Psychedelics Executive Order Accelerates Research

1 day agoNewsfilter

Research Acceleration: The White House's executive order aims to expedite research on psychedelics like psilocybin and MDMA, reinforcing a medical and evidence-based framework without altering their legal status, potentially paving the way for industry legitimization.
Clinical Trial Expansion: The order directs the FDA to expand clinical trials and 'Right to Try' access for patients with serious mental health conditions, which is expected to enhance patient access to new therapies and drive market potential for psychedelics.
Positive Market Reaction: Following the order's signing, psychedelic-focused companies like Atai Beckley saw stock prices rise by approximately 25%, indicating a positive market response to the policy shift and potentially attracting more investor interest in this emerging sector.
Safety Concerns: While the order emphasizes research acceleration, safety issues, particularly regarding ibogaine's cardiac risks, remain significant barriers, and the true value of these substances in the medical field will depend on the effectiveness of future implementations.